MGC Pharmaceuticals Limited Application for Admission to Trading (0711I)
August 02 2023 - 4:25AM
UK Regulatory
TIDMMXC
RNS Number : 0711I
MGC Pharmaceuticals Limited
02 August 2023
MGC Pharmaceuticals Ltd
Compliance Release - Application for Admission to Trading
2 August 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ( " MGC Pharma " or the " Company ") is
applying for admission to the Financial Conduct Authority's
Official List and to trading on the Main Market of London Stock
Exchange plc ("Admission) of 87,353,469 fully paid Ordinary Shares
("Shares") previously issued by MGC Pharma. Admission of the Shares
is expected to take place at 8:00am (British Summer Time) on 9
August 2023.
Details of the 87,353469 Shares for which these applications
have been lodged are as follows:
-- 21,511,545 shares issued to Mercer in 2022 pursuant to a financing agreement.
-- 65,841,924 shares issued in 2022 as consideration for the 40%
acquisition of ZAM Software Limited.
The Shares are already quoted on the ASX and application for
Admission will not affect the Total Voting Rights in the
Company.
- Ends -
Authorised for release by the Managing Director, for further
information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.co.uk info@mgcpharma.co.uk
UK IR/PR Advisers UK Brokers
IFC Advisory Oberon Capital
Graham Herring / Tim Metcalfe Aimee McCusker / Adam
/ Zach Cohen Pollock
+44 203 934 6630 +44 203 179 5300
mgcpharma@investor-focus.co.uk aimeemccusker@oberoninvestments.com
adampollock@oberoninvestments.com
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing and supplying
accessible and ethically produced plant derived medicines,
combining in-house research with innovative technologies, with the
goal of finding or producing treatments to for unmet medical
conditions.
The Company's founders and executives are key figures in the
global pharmaceuticals industry and the core business strategy is
to develop and supply high quality plant derived medicines for the
growing demand in the medical markets in Europe, North America and
Australasia.
MGC Pharma has a robust development pipeline targeting two
widespread medical conditions and has further products under
development.
MGC Pharma has partnered with renowned institutions and academia
to optimise the development of targeted plant derived medicines, to
be produced in the Company's EU-GMP Certified manufacturing
facilities.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceutica
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGCGDIGDGDGXD
(END) Dow Jones Newswires
August 02, 2023 05:25 ET (09:25 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Apr 2024 to May 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From May 2023 to May 2024